Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Fei Li, Zhen Cai, Xiaojing Yan, Xianqi Feng, Wuping Li, Xiangmin Tong, Zengjun Li, Yuzhang Liu, Feifei Che, Xin'ai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang, Lugui Qiu

Blood (2025) 146 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2025-4049

Published: 2025

Journal Articles

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma

Yuxuan Che, Ruolan Zeng, Dabei Tang, Ou Bai, Youchao Jia, Yuhuan Gao, Xiaojing Yan, Xiaolei Ding, Xiuli Sun, Xiaobo Wang, Bing Xu, Hui-Han Wang, Dongxia Qu, Liye Xu, Na Li, Qingyuan Zhang, Hui Zhou, Xiuhua Sun

Blood (2025) 146 (Supplement 1): 7142.

https://doi.org/10.1182/blood-2025-7142

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

Qun Li, Xiaojing Yan, Jian-Qing Mi, Aijun Liao, Bingzong Li, Hui-Han Wang, Huili Cai, Yafei Wang, Li Cai, Yu Hu, Chunyan Sun

Blood (2025) 146 (Supplement 1): 3984.

https://doi.org/10.1182/blood-2025-3984

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Blood (2025) 146 (Supplement 1): 1919.

https://doi.org/10.1182/blood-2025-1919

Published: 2025

Journal Articles

Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement

Blood (2025) 146 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2025-1979

Published: 2025

Journal Articles

Real-world study of rituximab, methotrexate, and zanubrutinib (R-MZ) in the treatment of newly diagnosed primary central nervous system lymphoma

Bian Renjie, Jigang Wang, Yanming Pei, Xiaojing Yan

Blood (2025) 146 (Supplement 1): 3699.

https://doi.org/10.1182/blood-2025-3699

Published: 2025

Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Blood (2025) 146 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2025-3689

Published: 2025

Journal Articles

Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study

Xiaojing Yan, Jingchen Sui

Blood (2025) 146 (Supplement 1): 7204.

https://doi.org/10.1182/blood-2025-7204

Published: 2025

Journal Articles

Stratos: An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study

Blood (2025) 146 (Supplement 1): 120.

https://doi.org/10.1182/blood-2025-120

Published: 2025

Journal Articles

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Blood (2025) 146 (Supplement 1): 6293.

https://doi.org/10.1182/blood-2025-6293

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit Acute Myeloid Leukemia (AML): A multicenter, open-label prospective study

Ligen Liu, Li Yang, Fangli Chen, Li Chang, Limin Zhao, Xiang Zhou, Chunrong Ying, Yingting Lu, Hong Liang, Yuansong Bai, Wenzhong Wu, Xiaojing Yan, Jinhai Ren, Si Li, Yang Yu, Laigen Tong, Deng Pan

Blood (2025) 146 (Supplement 1): 1685.

https://doi.org/10.1182/blood-2025-1685

Published: 2025

Journal Articles

The Efficacy and Survival Analysis of Fit-AML Patients Treated with Venetoclax Combined with Hypomethylating Agents (VEN-HMAs)

Ludan Zhang, Jingchen Sui, Pingping Wang, Deng Pan, Xiaojing Yan

Blood (2024) 144 (Supplement 1): 5985.

https://doi.org/10.1182/blood-2024-209635

Published: 2024

Journal Articles

Early Bone Marrow Evaluation of Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients

Ludan Zhang, Pingping Wang, Deng Pan, Xiaojing Yan

Blood (2024) 144 (Supplement 1): 5984.

https://doi.org/10.1182/blood-2024-209559

Published: 2024

Journal Articles

SLC25A1 Reprograms Mitochondrial and Fatty Acid Metabolism to Promote the Progression of Acute Myeloid Leukemia

Xiaojing Yan, Miao Chen, Yuan Tao, Sijing Kang, Pengjie Yue, Rui Ge

Blood (2024) 144 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2024-203227

Published: 2024

Journal Articles

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2024-198959

Published: 2024

Journal Articles

Prognosis Prediction By Two Single Factors Could Predict the Survival of PCNSL Patients Received HD-MTX Therapy without HSCT

Bian Renjie, Yi Qu, Danyang Wu, Jinxiang Yu, Xiaoxue Wang, Lei Wang, Juan He, Jun Wang, Xiaojing Yan

Blood (2024) 144 (Supplement 1): 6466.

https://doi.org/10.1182/blood-2024-204890

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement

Real-world study of rituximab, methotrexate, and zanubrutinib (R-MZ) in the treatment of newly diagnosed primary central nervous system lymphoma

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study

Stratos: An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit Acute Myeloid Leukemia (AML): A multicenter, open-label prospective study

The Efficacy and Survival Analysis of Fit-AML Patients Treated with Venetoclax Combined with Hypomethylating Agents (VEN-HMAs)

Early Bone Marrow Evaluation of Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients

SLC25A1 Reprograms Mitochondrial and Fatty Acid Metabolism to Promote the Progression of Acute Myeloid Leukemia

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Prognosis Prediction By Two Single Factors Could Predict the Survival of PCNSL Patients Received HD-MTX Therapy without HSCT

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only